Sciele Pharma Completes Phase III Safety Trial Of Glycopyrrolate

7/8/2008 1:14 PM ET (RTTNews) - Pharmaceutical company Sciele Pharma, Inc. (SCRX: ) on Tuesday announced the completion of Phase III safety trial of glycopyrrolate to treat chronic, moderate-to-severe drooling in pediatric patients. The company said that the trial was designed to evaluate safety parameters for glycopyrrolate over a six-month period. The moderate-to-severe drooling in pediatric patients often result from cerebral palsy as well as from other neurological disorders. Glycopyrrolate received orphan drug designation from the US Food and Drug Administration, or FDA, in June 2006. Following the FDA approval, the Orphan Drug Act provides drug market exclusivity for a period of seven years for a product's orphan indication. Chief medical officer of Sciele Pharma, Larry Dillaha commented, "With the timely completion of... [read full story]